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Cold Spring Harbor, NY 11724, USASee Article, pages 681–689Cellular senescence is a process characterized by permanent cell
cycle arrest. It is the consequence of the ﬁnite proliferative capac-
ity of normal cells (replicative senescence) and the response to
stress and damage from exogenous and endogenous sources. Sev-
eral years ago it was shown that senescence is an innate tumour
suppressive mechanism associated with the activation of onco-
genes, which limits the progression of pre-malignant lesions
[1]. As a consequence, escape from senescence is a prerequisite
for the progression to malignancy. There are three main mecha-
nisms that trigger cellular senescence and that must be quelled
in cancer cells: activation of the p53 pathway, upregulation of
the CDKN2A locus, and telomere shortening [2]. Genetic and epi-
genetic aberrations in any or all of these pathways are common
marks of all types of human cancer. However, the senescence
resistance associated with transformed cells is reversible [3],
and senescence-inducing drugs could represent an ideal opportu-
nity to increase the arsenal of anti-cancer weapons [2]. In the
present issue of The Journal of Hepatology the work of Ménard
et al. describes a new example of tumour progression blockage
linked to the induction of replicative senescence in a xenograft
model of liver cancer [4].
Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer in the world and is characterized by a poor prognosis. In
many cases no effective therapy at all can be offered to patients
with HCC [5]. Surgical interventions such as tumour ablation or
transplantation are restricted to a selected group of patients with
very speciﬁc clinical features, and non-resectable tumours are
resistant to conventional chemotherapy. New strategies such as
radiotherapy and gene therapy alone or in combination with cell
therapy are at early stages of clinical development [6]. Given the
survival beneﬁts of the molecular inhibitor Sorafenib in patients
at advanced stages [7] the use of single or combined targeted
therapies appears as a promising therapeutic alternative. Recent
studies demonstrate the existence of an increasing number of
pathways that might be altered by drugs in HCC cells [5]. The
molecular proﬁling of HCC and the identiﬁcation of patient sub-
classes according to drug responsiveness will lead to a more per-Journal of Hepatology 20
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ciated heterochromatin foci; shRNA, short hairpin RNA; TUNEL, terminal deoxy-
nucleotidyl transferase-mediated dUTP nick end labelling.sonalized and effective medicine. As in other types of tumours,
aberrations in senescence pathways such as mutations in p53,
epigenetic silencing of p16INK4a or induction of telomerase are
present in a majority of HCCs [8], representing critical targets
for therapeutic intervention.
Telomerase is a ribonucleoprotein complex that adds DNA
repeats to the ends of the chromosomes to stabilize them. The
upregulation of telomerase expression is a hallmark of cancer
cells; therefore, the development of efﬁcient telomerase inhibi-
tors represents a challenge and an opportunity for anti-cancer
therapy. Recently it has been shown that the ATPases Pontin
and Reptin are essential for the assembling of the telomerase
complex [9]. This ﬁnding implies that inhibitors of Pontin and
Reptin might act as highly effective therapeutic drugs targeting
telomerase in human cancer.
Pontin and Reptin are ATP binding proteins that belong to the
AAA+ (ATPase associated with diverse cellular activities) family of
ATPases which are normally co-expressed and form preferentially
heteromeric complexes. They participate in different chromatin
remodelling complexes, where they regulate the accessibility of
DNA to nuclear proteins in processes such as gene transcription
and DNA damage response [10]. Through their chromatin remod-
elling activity Pontin and Reptin also regulate the functions of the
oncogenes c-myc and b-catenin, and have been implicated in cell
transformation and metastasis [11]. In addition, both ATPases
participate in the assembly and maturation of snoRNPs (small
nucleolar RNPs) and as mentioned above in the assembly and
function of the RNP complex of telomerase [9].
Using a differential proteomic analysis to look for new HCC
targets, the group led by Dr. Rosenbaum previously uncovered
the overexpression of Pontin [12] and Reptin [13] in HCC. They
demonstrated that Reptin and Pontin expression is associated
with poorly differentiated tumours and that both proteins could
be considered markers of poor prognosis [12,13]. Immunohisto-
chemical analysis of Reptin and Pontin expression in HCC showed
that both proteins are expressed not only in the nucleus but also
in the cytoplasm of tumour cells, suggesting possible new cyto-
plasmic functions related to their pro-tumorigenic activity
[12,13]. In the different complexes that they are presented, Rep-
tin and Pontin are found in a 1:1 stoichiometry. In a recent work
from this same group, Haurie and coworkers demonstrated the
existence of a tight and reciprocal regulation of both proteins
[12]. Using speciﬁc siRNAs the authors observed that the10 vol. 52 j 633–634
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transcription and translation of the partner protein were not
altered. However, the newly synthesized Pontin or Reptin is
degraded by the proteasome when either Reptin or Pontin are
depleted [12]. Regarding the function of these ATPases in HCC,
the same authors demonstrated that both proteins play essential
roles in the survival of hepatoma cells. The silencing of either of
the proteins in Huh7 or Hep3B human hepatoma cells results in
the reduction of cell growth and the induction of apoptosis
[12,13]. The role of these proteins in hepatocarcinogenesis is
reinforced by the fact that the overexpression of Reptin in
Huh7 cells enhances tumorigenicity [13].
All these results together indicate that these proteins indeed
play a role in the biology of the HCC cell, and suggest that both
ATPases may represent new therapeutic targets in liver cancer.
In the current issue of The Journal of Hepatology Ménard and
coworkers undertake the in vivo validation of this hypothesis.
To this end they use a doxycycline (Dox)-inducible shRNA system
to knockdown the expression of Reptin in already established
xenograft tumours in mice. The authors ﬁrst ﬁnely characterize
in vitro the speciﬁcity and inducibility of the shRNA that they
subsequently use in vivo. They show that the inhibitory effect
on cell growth observed upon Reptin-shRNA transfection in
Huh7 cells is reversed or rescued after transfection with a
shRNA-resistant Reptin construct. Conﬁrming their previous
results [12,13], they demonstrate that Reptin knockdown in
Huh7 and Hep3B cells arrests cell growth and induces apoptosis.
In agreement with previous observations from other groups,
Ménard and coworkers conﬁrm that Reptin silencing in hepa-
toma cells signiﬁcantly reduces telomerase activity and induces
senescence.
In vivo, the authors use these engineered Huh7 and Hep3B
human HCC cell lines to induce subcutaneous tumours in NOD/
SCID mice. In order to evaluate the effect of Reptin silencing in
a therapeutic situation, they administered Dox, to knockdown
the expression of Reptin, to mice that harboured established
tumours. Upon Dox administration tumour growth not only
stopped but even regressed in mice expressing the Reptin speciﬁc
shRNA. This effect was associated with a signiﬁcant inhibition on
Reptin expression and decreased cell proliferation, but not with a
higher level of apoptosis quantiﬁed as TUNEL-positive cells. How-
ever, the blockage of tumour growth upon Reptin silencing was
associated with the induction of senescence, as shown by the
increase in senescence markers such as acid b-galactosidase
staining and senescence-associated heterochromatin foci (SAHF).
These results present Reptin as a new therapeutic target in
HCC and the use of speciﬁc Reptin/Pontin ATPase inhibitors as
an encouraging alternative for the treatment of cancer in general.
However, as the authors discuss, the evidence suggesting that the
ATPase activity of Reptin is required in oncogenesis is only cir-
cumstantial and further experiments are required to clarify this
point.
The work by Ménard and coworkers also raises other interest-
ing questions to be solved. Replicative or telomere-dependent
senescence has been linked to the induction of a DNA damage
response and the activation of the p53 pathway. However, the
two hepatoma cell lines used in the present study are devoid of
p53 activity, indicating that alternative pathways are involved
in Reptin depletion-mediated induction of senescence. As previ-
ously mentioned, in tumour cells, including HCC cells, Reptin
accumulates both in the nucleus and in the cytoplasm [11]. Inter-634 Journal of Hepatology 201estingly, the authors observed that cytosolic Reptin was preferen-
tially depleted upon Reptin-shRNA induction, and that the
cytosolic downregulation of Reptin was accompanied by a clear
inhibition of tumour growth. The reason for this preferential
downregulation of extranuclear Reptin is currently unknown;
however, these ﬁndings are suggestive of a pro-tumorigenic
effect of this protein in the cytosolic compartment that warrants
further investigation. Although cellular senescence is a cytostatic
process, tumour regression occurs. The authors explain this effect
as a result of the induction of apoptosis as a secondary event;
however, other authors associate tumour clearance with the
cooperation between cellular senescence and the evoked inﬂam-
matory response [3]. To gain further insight into these and other
aspects of Reptin contribution to liver cancer, it would be inter-
esting to examine the behaviour of liver-speciﬁc Reptin knockout
mice undergoing chemically-induced carcinogenesis.
In summary, the work of Ménard and coworkers uncovers
novel targeted therapeutics to re-engage the disrupted senes-
cence program in liver cancer.Conﬂicts of interest
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